June 2, 2025 8:12am
Get back-in and re-test the sector waters after May’s cell and gene therapy sector ‘s month
alternations, nibble!
News: Sanofi (SAN) to buy Blueprint Medicines (BPMC +$26.97 or +26.76 to $128.21) for Up to $9.5 Billion in boost to pipeline <WSJ>
Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering share pricing so far this ‘25
The cell and gene therapy sector followed the markets’ steering related to tariff uncertainties amid signs of cooling inflation; yet, all 3 major indices finished both the week and the month in the green
Pre-open Indications: 4 Negative and 3 Positive
No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief
Never leave an investor uninformed!
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!
More News: ASCO this week. REGENXBIO (RGNX +$0.20 pre-open) new interim functional data from the P1/2 AFFINITY DUCHENNE® trial of RGX-202, gene therapy for the treatment of Duchenne muscular dystrophy. uniQure N.V. (QURE +$0.02) Following recent Type B meetings and further guidance from the FDA, QURE has reached alignment with the FDA on several key components of the statistical analysis plan and Chemistry, Manufacturing and Controls (CMC) information that will support a Biologics License Application (BLA) submission expected in Q1/26.
Friday’s night’s … RegMed Investors (RMi) Closing Bell: the blessing and curses … https://www.regmedinvestors.com/articles/13940
RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): No partner, No cash, NO runway, extensive liabilities and debts to past employee and university associations … https://www.regmedinvestors.com/articles/13812
Monday: The pre-open Dow futures are DOWN -0.26% or (-109 points), the S&P futures are DOWN -0.35% or (-21 points) and the Nasdaq futures are DOWN -0.50% or (-107 points)
- Stock futures fell Monday, 1st trading session of June,
- European stock markets opened lower,
- Asia-Pacific markets mostly lower.
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
Friday: The Dow closed UP +54.34 points or +0.13%, the S&P closed DOWN -0.48 points or -0.01% while the Nasdaq closed DOWN -62.11 points or -0.32%
On Friday, closing out the month of May the S&P 500 gained 6%, its best monthly performance since November 2023. The Nasdaq surged more than 9% for the month and the Dow rose about 4%.
Economic Data Docket: S&P final U.S. manufacturing PMI (May), ISM manufacturing (May), Construction spending (April), Dallas Fed President Lorie Logan, Chicago Fed President Austan Goolsbee speech and Auto sales.
Q2 – June – 1st session
- May – 1 market holiday, 10 negative and 11 positive closes
- Q2 - April – 10 negative and 11 positive closes
Q1/25
- March, 10 positive and 11 negative closes
- February – 12 holiday, 11 negative and 7 positive closes
- January - 2 holidays, 1 market close, 10 negative and 10 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the … econs, it is still a mix of ups, downs and just uncertainty
Although:
Beam Therapeutics (BEAM) closed down -$0.49 with a negative -$0.39 or -2.46% aftermarket
CRISPR Therapeutics (CRSP) closed down -$0.49 with a negative -$0.10 or -0.28%
Moderna (MRNA) closed down -$0.37 with a negative -$0.04 or -0.15%
Ultragenyx Pharmaceuticals (RARE) closed down -$1.00 with a negative -$0.03 or -0.09%
Agenus (AGEN) closed up +$0.23 with a positive +0.23 or +7.187%
Caribou Biosciences (CRBU) closed down -$0.10 with a positive +$0.03 or +2.83%
Verve Therapeutics (VERV) closed down -$0.15 with a positive +0.078 or +1.757%
The BOTTOM LINE: Not a clairvoyant, there are session that are just a flip-of-the-coin
- Although an acquisition (in title) puts the flashlight on the current crop of cell and gene companies!!
Relating to the title, “the extra potential of the summer rally (relative to the average of other months) is quite modest - just 90 basis points, or 0.9%. Finally, you would need extraordinary clairvoyance to realize this additional gain, since only in retrospect can you know the stock market's highest close over a 3-month period.”
Fears of tariff-induced inflation have failed to be realized.
- The Personal Consumption Expenditures Price Index, the Fed’s favored metric, slipped in April, while consumer confidence is picking up. The May payrolls report, due June 6, will be the next test. <MarketWatch>
May ’25 last week: understand the “flow” of bad market and economic karma…
- 5/30 – Friday closed negative with 6 positive, 26 negative and 3 flats
- 5/29 –Thursday closed positive with 24 positive, 10 negative and 1 flat
- 5/28 -Wednesday closed negative with 7 positive, 26 negative and 2 flats
- 5/27 - Tuesday closed positive with 21 positive, 11 negative and 3 flats
- 5/26 - Monday. Market closed - holiday
As always, brace ourself for more volatility, economics and their down trending affect?
Welcome to my world of defining the “grey’ in our universe!
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.
I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.
